{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:12:43Z","timestamp":1793502763839,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021490","name":"National Center for Inter-University Research Facilities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021490","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jconrel.2024.08.012","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T09:54:57Z","timestamp":1724406897000},"page":"337-348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Engineered lipid nanoparticles enable therapeutic gene silencing of GTSE1 for the treatment of liver fibrosis"],"prefix":"10.1016","volume":"374","author":[{"given":"Michaela","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyeongseok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Bhin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisoo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Sun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonhyo","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyukjin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.08.012_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0010","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2020.06.002","article-title":"Lipid nanoparticles for nucleic acid delivery: current perspectives","volume":"154-155","author":"Samaridou","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0020","first-page":"181","article-title":"Lipids and lipid derivatives for RNA delivery","volume":"1","author":"Zhang","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0025","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1172\/JCI31487","article-title":"Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases","volume":"117","author":"Wynn","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0030","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.3748\/wjg.v20.i23.7260","article-title":"Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: an update","volume":"20","author":"Elpek","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41467-022-35637-z","article-title":"Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis","volume":"14","author":"Han","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hep.27936","article-title":"Specific hepatic delivery of procollagen alpha1(I) small interfering RNA in lipid-like nanoparticles resolves liver fibrosis","volume":"62","author":"Jimenez Calvente","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2024.08.012_bb0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1021\/acs.molpharmaceut.7b00709","article-title":"pPB peptide-mediated siRNA-loaded stable nucleic acid lipid nanoparticles on targeting therapy of hepatic fibrosis","volume":"15","author":"Jia","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0050","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jconrel.2022.12.020","article-title":"Self-homing nanocarriers for mRNA delivery to the activated hepatic stellate cells in liver fibrosis","volume":"353","author":"Younis","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.08.012_bb0055","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jconrel.2023.08.021","article-title":"Reprogramming activated hepatic stellate cells by siRNA-loaded nanocarriers reverses liver fibrosis in mice","volume":"361","author":"Younis","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.08.012_bb0060","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.xphs.2017.04.042","article-title":"The delivery of small interfering RNA to hepatic stellate cells using a lipid nanoparticle composed of a vitamin A-scaffold lipid-like material","volume":"106","author":"Toriyabe","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fphar.2016.00033","article-title":"Pharmacological intervention in hepatic stellate cell activation and hepatic fibrosis","volume":"7","author":"Schon","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0070","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","article-title":"Targeting fibrosis: mechanisms and clinical trials","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0075","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10565-016-9327-z","article-title":"Silencing GTSE-1 expression inhibits proliferation and invasion of hepatocellular carcinoma cells","volume":"32","author":"Guo","year":"2016","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0080","article-title":"GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep-Uk"},{"key":"10.1016\/j.jconrel.2024.08.012_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202209432","article-title":"Engineered lipid nanoparticles for the treatment of pulmonary fibrosis by regulating epithelial-mesenchymal transition in the lungs","volume":"33","author":"Jin","year":"2023","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0090","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/gut.2008.174904","article-title":"Hepatocyte nuclear factor 4alpha attenuates hepatic fibrosis in rats","volume":"59","author":"Yue","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2024.08.012_bb0095","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10556","article-title":"Novel piperazine-based ionizable lipid nanoparticles allow the repeated dose of mRNA to fibrotic lungs with improved potency and safety","volume":"8","author":"Kim","year":"2023","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.jconrel.2024.08.012_bb0100","article-title":"Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver","volume":"7","author":"Kim","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0105","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10213","article-title":"Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles","volume":"6","author":"Schlich","year":"2021","journal-title":"Bioeng Transl Med"},{"key":"10.1016\/j.jconrel.2024.08.012_bb0115","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.omtn.2017.11.005","article-title":"Rapid, Single-Cell Analysis and Discovery of Vectored mRNA Transfection In Vivo with a loxP-Flanked tdTomato Reporter Mouse","volume":"10","author":"Kauffman","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jconrel.2024.08.012_bb0125","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1113\/JP281061","article-title":"Hepatic stellate cells in physiology and pathology","volume":"600","author":"Kamm","year":"2022","journal-title":"J. Physiol."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0130","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nprot.2015.017","article-title":"High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers","volume":"10","author":"Mederacke","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0135","first-page":"74","article-title":"Lipid nanoparticle delivery systems for siRNA-based therapeutics, drug Deliv","volume":"4","author":"Wan","year":"2014","journal-title":"Transl. Res."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13506129.2016.1160882","article-title":"Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis","volume":"23","author":"Butler","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.jconrel.2024.08.012_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/jcm5030030","article-title":"Circulating microRNAs as potential biomarkers in non-alcoholic fatty liver disease and hepatocellular carcinoma","volume":"5","author":"Afonso","year":"2016","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0150","first-page":"586","article-title":"Role of circulating microRNAs in liver diseases, world","volume":"9","author":"Loosen","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-015-0623-9","article-title":"Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis","volume":"13","author":"Momen-Heravi","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0160","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jhep.2019.06.018","article-title":"ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles","volume":"71","author":"Seo","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0165","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0170","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ng1175","article-title":"Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis","volume":"34","author":"Parviz","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0175","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jhep.2021.08.011","article-title":"Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model","volume":"75","author":"Yang","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0180","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3748\/wjg.v22.i48.10512","article-title":"Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets","volume":"22","author":"Zhang","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0185","article-title":"A combinatorial library of lipid nanoparticles for cell type-specific mRNA delivery","volume":"10","author":"Naidu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.jconrel.2024.08.012_bb0190","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0195","doi-asserted-by":"crossref","DOI":"10.1038\/s41565-022-01146-9","article-title":"Nanoparticle single-cell multiomic readouts reveal that cell heterogeneity influences lipid nanoparticle-mediated messenger RNA delivery","volume":"17","author":"Dobrowolski","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0200","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1021\/acs.molpharmaceut.2c00033","article-title":"Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells","volume":"19","author":"Ferraresso","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.08.012_bb0205","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fimmu.2020.00218","article-title":"Targeting of hepatic macrophages by therapeutic nanoparticles","volume":"11","author":"Colino","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924005510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T10:43:54Z","timestamp":1741257834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924005510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":41,"alternative-id":["S0168365924005510"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.08.012","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineered lipid nanoparticles enable therapeutic gene silencing of GTSE1 for the treatment of liver fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}